To determine whether the observed synergy between CSF3RT618I and CEBPAV314VW was more broadly generalizable, we looked for other mutations that co-occur with CEBPA in AML, which like CSF3RT618I, also activate the JAK/STAT pathway. This evidence concerns the gene CEBPA and acute myeloid leukemia.